Skip to main navigation
USA USA English
Brazil Brazil Português
Canada Canada English Français
Japan Japan Japanese
  • Blog
  • Patient Resources
  • Investors & Media
  • Careers top menu  Careers
  • Contact
Ultragenyx Logo
  • Our Purpose
    • Our Commitment to Patients
      • Rare Disease Day
    • Supporting Access for Patients
      • Approved Medicines
      • Investigational Therapies
      • Patient/Advocacy Resources
    • Corporate Sustainability
      • Charitable Grants and Donations
  • Our Company
    • Our Leaders
    • Our Partners
    • Contact Us
  • Our Medicines
    • Crysvita® (burosumab-twza)
    • Dojolvi® (triheptanoin)
    • Mepsevii® (vestronidase alfa—vjbk)
  • Our Research
    • Our Science
    • Our Pipeline
      • DTX401 for GSDIa
      • DTX301 for OTC
      • UX701 for Wilson Disease
      • UX143 for Osteogenesis Imperfecta
      • GTX-102 for Angelman Syndrome
      • UX053 for GSDIII
      • Our Clinical Trial Transparency Commitment
    • Our Gene Therapy Platform
  • Blog
  • Patient Resources
  • Investors & Media
  • Careers mobile menu   Careers
  • Contact

Committee Composition

Audit Nominating and Corporate Governance Compensation Research and Development
Emil D. Kakkis M.D., Ph.D. Research and Development
Amrit Ray M.D., M.B.A. Research and Development
Lars Ekman M.D., Ph.D Research and Development
Deborah Dunsire, M.D. Compensation
Daniel G. Welch Nominating and Corporate Governance Compensation
Matthew K. Fust Audit Nominating and Corporate Governance
Michael Narachi Audit Compensation
Corsee Sanders, Ph.D. Audit Research and Development
Shehnaaz Suliman M.D. Nominating and Corporate Governance Research and Development
= Chairperson = Member = Chairman of the Board

INVESTORS & MEDIA

  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Management
    • Board of Directors
    • Committee Composition
    • Corporate Sustainability
  • SEC Filings
  • Stock Information
  • Analyst Coverage
  • Investor FAQ
  • Contact Us

SHAREHOLDER TOOLS

  • Print
  • Email Alerts
  • RSS Feeds

You are about to leave the Ultragenyx website.

Do you want to continue?

Ultragenyx is not responsible for the content or availability of third party sites.

  • Our Purpose
    • Our Commitment to Patients
    • Supporting Access for Patients
    • Corporate Sustainability
  • Our Company
    • Our Leaders
    • Our Partners
    • Contact Us
  • Our Medicines
    • Crysvita® (burosumab-twza)
    • Dojolvi® (triheptanoin)
    • Mepsevii®(vestronidase alfa—vjbk)
  • Our Research
    • Our Science
    • Our Pipeline
    • Our Gene Therapy Platform
  • Careers
    • Culture
    • Benefits
    • Talent Network
    • Emerging Talent
    • Jobs
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Governance
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • Investor FAQ
Our Other Websites
  • www.UltraRareAdvocacy.com
  • www.UltraCareSupport.com
Ultragenyx Logo
  • Linkedin
  • Facebook

©2023 Ultragenyx Pharmaceutical Inc.. All rights reserved.

  • Privacy Policy
  • Cookie Policy